Zenas BioPharma, Inc. (ZBIO) Earnings History
Net Loss4 years of earnings data (2022–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Zenas BioPharma, Inc. (ZBIO) Earnings Overview
As of July 6, 2026, Zenas BioPharma, Inc. (ZBIO) reported trailing twelve-month net income of -$425M, reflecting -124.5% year-over-year growth. The company earned $-7.64 per diluted share over the past four quarters, with a net profit margin of -3777.4%.
Looking at the long-term picture, ZBIO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$37M in fiscal 2023.
Zenas BioPharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ARCT (-$79M net income, -97.9% margin), IMVT (-$506M net income), ARDX (-$58M net income, -15.1% margin), ZBIO has room to improve margins relative to the peer group. Compare ZBIO vs ARCT →
ZBIO Earnings vs Peers
Earnings metrics vs comparable public companies
ZBIO Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$378M | -140.6% | -$211M | $-8.44 | -3777.4% | -2113.8% |
| 2024 | -$157M | -322.9% | -$164M | $-3.76 | -3139.8% | -3277.8% |
| 2023 | -$37M | +68.9% | -$37M | $-0.97 | -74.2% | -74.3% |
| 2022 | -$119M | - | -$76M | $-3.11 | - | - |
Download Data
Export ZBIO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ZBIO — Frequently Asked Questions
Quick answers to the most common questions about buying ZBIO stock.
What is ZBIO earnings per share (EPS)?
ZBIO trailing twelve-month (TTM) diluted EPS is $-7.64, reflecting -124.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2022 to 2025 is available in the table on this page.
What is Zenas BioPharma, Inc.'s net income?
Zenas BioPharma, Inc. (ZBIO) trailing twelve-month net income is $-425M as of 2025. Earnings declined -124.5% year-over-year.
Is ZBIO profitable?
ZBIO is not currently profitable on a TTM basis, reporting a net loss of $-425M. Net margin is -3777.4%. Investors should monitor for a return to profitability.
What is ZBIO's earnings growth rate?
ZBIO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2022 to 2025.
What are ZBIO's profit margins?
Zenas BioPharma, Inc. net profit margin is -3777.4%, operating margin is -2113.8%, and gross margin is +100.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -136.2%.
Is ZBIO growing earnings?
ZBIO earnings are declining — EPS fell -124.5% year-over-year. TTM net income dropped to $-425M. This contrasts with the 5-year CAGR of N/A.
What was ZBIO's best earnings year?
Zenas BioPharma, Inc.'s highest annual net income on record is $-37M, achieved in fiscal year 2023. Earnings history on this page spans 2022 to 2025 and includes all annual and quarterly figures.
What were ZBIO's earnings last quarter?
ZBIO's most recent reported quarter was Q1 2026. Net income was $-81M with diluted EPS of $-1.46. For a full breakdown of all quarters, see the quarterly earnings table on this page.